{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~24 mi. (Naples, Italy, +192 more cities)
facility
University of Naples Federico II
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~24 mi. (Naples, Italy, +76 more cities)
facility
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
city
~24 mi. (Naples, Italy, +29 more cities)
facility
University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704)
condition
Pancreatic Neuroendocrine Tumor, +1 more condition
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
city
~24 mi. (Naples, Italy, +44 more cities)
facility
National Cancer Institute
biomarker
BCL2 Fusion, +2 more biomarkers
condition
Diffuse Large B-Cell Lymphoma, +3 more conditions
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +3 more types
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~27 mi. (Napoli, Italy, +383 more cities)
facility
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~27 mi. (Napoli, Italy, +140 more cities)
facility
Ospedale del Mare ( Site 0327)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~27 mi. (Napoli, Italy, +122 more cities)
facility
A.O.R.N. Antonio Cardarelli
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~27 mi. (Napoli, Italy, +262 more cities)
facility
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~27 mi. (Napoli, Italy, +260 more cities)
facility
Università degli Studi Federico II; Clinica di Oncologia Medica, +1 more facility
biomarker
ERBB2 Amplification, +1 more biomarker
drug type
immunotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~27 mi. (Napoli, Italy, +115 more cities)
facility
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, +1 more facility
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type